Brookline Capital Management Initiates Coverage on Palisade Bio (NASDAQ:PALI)

Brookline Capital Management started coverage on shares of Palisade Bio (NASDAQ:PALI) in a report issued on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $38.00 target price on the stock.

Separately, Maxim Group decreased their price target on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Palisade Bio Price Performance

Palisade Bio stock opened at $2.44 on Wednesday. Palisade Bio has a fifty-two week low of $2.18 and a fifty-two week high of $22.35. The firm has a market capitalization of $3.25 million, a PE ratio of -0.17 and a beta of 1.36. The company’s 50-day moving average is $3.21 and its 200-day moving average is $3.98.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter, beating analysts’ consensus estimates of ($3.35) by $1.03. As a group, analysts expect that Palisade Bio will post -13.11 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.